Switzerland-based SOPHiA Genetics (Nasdaq: SOPH) has signed a memorandum of understanding with Memorial Sloan Kettering Cancer Center to form a joint venture aimed at building a global precision medicine hub. The proposed hub would combine MSK's clinical genomic datasets and oncology expertise with SOPHiA's SOPHiA DDM AI analytics platform, targeting companion diagnostic development, clinical algorithm generation, and evidence production for biopharma partners. The announcement builds on a prior licensing relationship in which SOPHiA deployed MSK's proprietary assays across 35 countries, but the joint venture structure would go considerably further by creating shared infrastructure for discovery and commercialization.
Financial terms were not disclosed, and the specifics of the joint venture remain unfinalized.
Deal context
The SOPHiA DDM platform, described by the company as an AI-native, cloud-based system for genomic and multimodal data analysis, would serve as the analytics backbone of the proposed hub. The platform applies machine learning models to next-generation sequencing data, supporting variant detection, clinical decision support, and companion diagnostic development. It has been used to analyze more than 2.5 million cases since 2014 and operates across a decentralized network of more than 990 hospitals and laboratories globally.
MSK's contribution centers on its in-house NGS program, which has sequenced more than 150,000 tumor samples since 2014, generating a dataset linked to clinical outcomes, pathology, and radiology records. The institution's proprietary assays — MSK-IMPACT, a solid tumor sequencing panel, and MSK-ACCESS, a liquid biopsy test for circulating tumor DNA — have already been integrated into the SOPHiA DDM platform under earlier license agreements and are now deployed at institutions in dozens of countries.
The proposed precision medicine hub is described as an incubation facility capable of moving discoveries from bench to clinical deployment faster than traditional models. For biopharma partners, the envisioned structure would provide dedicated infrastructure for next-generation companion diagnostics, clinical algorithm development, and real-world evidence generation — functions that are increasingly in demand as targeted therapies push molecular diagnostics earlier in the treatment pathway.